Humana Inc (NYSE:HUM) – Analysts at Leerink Swann lifted their FY2018 earnings estimates for shares of Humana in a research note issued on Thursday. Leerink Swann analyst A. Gupte now forecasts that the insurance provider will post earnings per share of $14.00 for the year, up from their prior forecast of $12.25. Leerink Swann currently has a “Outperform” rating and a $300.00 target price on the stock. Leerink Swann also issued estimates for Humana’s FY2019 earnings at $17.50 EPS and FY2020 earnings at $19.40 EPS.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, February 7th. The insurance provider reported $2.06 EPS for the quarter, topping the consensus estimate of $2.00 by $0.06. The company had revenue of $13.19 billion for the quarter, compared to analysts’ expectations of $13.14 billion. Humana had a return on equity of 16.13% and a net margin of 4.55%. The business’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.34 earnings per share.

Other equities analysts have also recently issued research reports about the company. JPMorgan Chase & Co. raised their price target on Humana from $253.00 to $271.00 and gave the company a “neutral” rating in a report on Monday. ValuEngine cut Humana from a “buy” rating to a “hold” rating in a report on Tuesday, December 19th. Credit Suisse Group assumed coverage on Humana in a report on Thursday, November 2nd. They issued a “neutral” rating and a $256.00 price target on the stock. Zacks Investment Research cut Humana from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 17th. Finally, Oppenheimer raised their price target on Humana from $275.00 to $305.00 and gave the company an “outperform” rating in a report on Thursday, February 8th. Seven investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $270.47.

Humana (NYSE:HUM) traded down $0.61 during trading on Monday, reaching $266.44. The company had a trading volume of 402,832 shares, compared to its average volume of 1,198,008. The company has a market capitalization of $36,528.92, a PE ratio of 22.70, a price-to-earnings-growth ratio of 1.44 and a beta of 0.93. Humana has a fifty-two week low of $203.36 and a fifty-two week high of $293.35. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.61 and a current ratio of 1.85.

The business also recently announced a quarterly dividend, which will be paid on Friday, April 27th. Shareholders of record on Friday, March 30th will be paid a $0.50 dividend. This is a positive change from Humana’s previous quarterly dividend of $0.40. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $2.00 annualized dividend and a yield of 0.75%. Humana’s dividend payout ratio is presently 9.59%.

Humana announced that its board has approved a share buyback program on Thursday, December 14th that allows the company to buyback $3.00 billion in outstanding shares. This buyback authorization allows the insurance provider to reacquire shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

In other news, SVP Jody L. Bilney sold 7,054 shares of the firm’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $247.89, for a total transaction of $1,748,616.06. Following the sale, the senior vice president now owns 11,704 shares of the company’s stock, valued at $2,901,304.56. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Brian P. Leclaire sold 1,679 shares of the firm’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $245.97, for a total value of $412,983.63. Following the sale, the senior vice president now directly owns 9,888 shares in the company, valued at approximately $2,432,151.36. The disclosure for this sale can be found here. Insiders sold 10,115 shares of company stock worth $2,501,627 in the last three months. Insiders own 0.80% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. WFG Advisors LP raised its position in shares of Humana by 4.5% during the second quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock worth $113,000 after purchasing an additional 20 shares during the period. Fieldpoint Private Securities LLC acquired a new stake in shares of Humana during the third quarter worth about $115,000. American Beacon Advisors Inc. acquired a new stake in shares of Humana during the fourth quarter worth about $122,000. ClariVest Asset Management LLC acquired a new stake in shares of Humana during the third quarter worth about $144,000. Finally, YorkBridge Wealth Partners LLC raised its position in shares of Humana by 99.0% during the fourth quarter. YorkBridge Wealth Partners LLC now owns 597 shares of the insurance provider’s stock worth $159,000 after purchasing an additional 297 shares during the period. 94.13% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://theolympiareport.com/2018/02/13/fy2018-eps-estimates-for-humana-inc-hum-boosted-by-leerink-swann.html.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.